







an Open Access Journal by MDPI

## **Vaccination Coverage, Efficacy and Attitude in Targeted Risk Groups**

Guest Editors:

## Dr. Marco Goeijenbier

Department of Intensive Care, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands

## Prof. Eric C.M. van Gorp

Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands

Deadline for manuscript submissions:

closed (31 December 2021)

# **Message from the Guest Editors**

Dear Colleagues,

We are soliciting articles for a Special Issue of MDPI *Vaccines*, which is entitled "Vaccination coverage, efficacy and attitude in targeted risk groups".

Vaccination, if available, has proven to be the most effective way of preventing and reducing the burden of many infectious diseases. However, two of the current biggest challenges in the field of vaccinology are the upcoming trend of vaccine hesitancy and the decreased efficacy in risk groups. In fact, if we are able to produce effective and safe vaccines but their uptake is low, the desired effect will not be achieved. Furthermore, vaccines effective in healthy adults could have a decreased effect in the immunocompromised and elderly.

An improved understanding of drivers of vaccine uptake and efficacy will enhance targeted interventions. In addition, due to the high heterogeneity of risk groups in general, one could learn a lot about the efficacy of interventions to increase vaccination uptake and efficacy.







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

## **Editor-in-Chief**

## Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## **Contact Us**